Review



rabbit antibody against human trim33  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Proteintech rabbit antibody against human trim33
    The expression of <t>TRIM33</t> in pan-cancer, and association between TRIM33 expression and the survival of patients with GC. (A) TRIM33 expression in 31 tumors from TCGA database. Red bars represent tumor samples, blue bars represent normal tissue samples. (B) OS, FPS, and PPS curves in patients with GC. (C) Survival curves of different pTNM stages in patients with GC. (D) Survival curves of different pT stages in patients with GC. * P < .05, ** P < .01, *** P < .001 versus normal tissue samples.
    Rabbit Antibody Against Human Trim33, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+antibody+against+human+trim33/pmc09358585-32-1-12?v=Proteintech
    Average 93 stars, based on 7 article reviews
    rabbit antibody against human trim33 - by Bioz Stars, 2026-07
    93/100 stars

    Images

    1) Product Images from "Downregulation of TRIM33 Promotes Survival and Epithelial–Mesenchymal Transition in Gastric Cancer"

    Article Title: Downregulation of TRIM33 Promotes Survival and Epithelial–Mesenchymal Transition in Gastric Cancer

    Journal: Technology in Cancer Research & Treatment

    doi: 10.1177/15330338221114505

    The expression of TRIM33 in pan-cancer, and association between TRIM33 expression and the survival of patients with GC. (A) TRIM33 expression in 31 tumors from TCGA database. Red bars represent tumor samples, blue bars represent normal tissue samples. (B) OS, FPS, and PPS curves in patients with GC. (C) Survival curves of different pTNM stages in patients with GC. (D) Survival curves of different pT stages in patients with GC. * P < .05, ** P < .01, *** P < .001 versus normal tissue samples.
    Figure Legend Snippet: The expression of TRIM33 in pan-cancer, and association between TRIM33 expression and the survival of patients with GC. (A) TRIM33 expression in 31 tumors from TCGA database. Red bars represent tumor samples, blue bars represent normal tissue samples. (B) OS, FPS, and PPS curves in patients with GC. (C) Survival curves of different pTNM stages in patients with GC. (D) Survival curves of different pT stages in patients with GC. * P < .05, ** P < .01, *** P < .001 versus normal tissue samples.

    Techniques Used: Expressing

    Knockdown of TRIM33 promoted the proliferation of BGC-823 and SGC-7901 cells. (A&B) Western blot analysis of TRIM33 expression in GES, BGC-823, MGC-803, and SGC-7901 cell lines. (C&D) Western blot analysis of TRIM33 protein expression in cells transfected with si-TRIM33 encoding plasmids. (E) CCK8 assays were used to measure BGC-823 and SGC-7901 cell viability in the control and si-TRIM33-transfected group; the viability of the si-TRIM33 transfection groups was enhanced. (F&G) EdU assays were used to evaluate proliferation in the control and si-TRIM33 transfection groups in BGC-823 cells; the percentage of EdU-positive cells in the si-TRIM33 group was significantly greater than in the control group. * P < .05, ** P < .01; ns, non-significant.
    Figure Legend Snippet: Knockdown of TRIM33 promoted the proliferation of BGC-823 and SGC-7901 cells. (A&B) Western blot analysis of TRIM33 expression in GES, BGC-823, MGC-803, and SGC-7901 cell lines. (C&D) Western blot analysis of TRIM33 protein expression in cells transfected with si-TRIM33 encoding plasmids. (E) CCK8 assays were used to measure BGC-823 and SGC-7901 cell viability in the control and si-TRIM33-transfected group; the viability of the si-TRIM33 transfection groups was enhanced. (F&G) EdU assays were used to evaluate proliferation in the control and si-TRIM33 transfection groups in BGC-823 cells; the percentage of EdU-positive cells in the si-TRIM33 group was significantly greater than in the control group. * P < .05, ** P < .01; ns, non-significant.

    Techniques Used: Knockdown, Western Blot, Expressing, Transfection, Control

    Downregulation of TRIM33 enhanced colony formation and migratory ability. (A&B) Downregulation of TRIM33 promoted colony formation in BGC-823 and SGC-7901 cells. (C&D) After 24 h, the number of cells passing through the Transwell membrane was higher in the si-TRIM33 group than in the control group (×100 magnification, corresponding to a scale of 200 μm). (E&F) After 12, 24, 48, 72, 96, 120, and 144 h, the width of the residual scratch was narrower in the si-TRIM33 group than in the control group (×100 magnification, corresponding to a scale of 200 μm). * P < .05, ** P < .01.
    Figure Legend Snippet: Downregulation of TRIM33 enhanced colony formation and migratory ability. (A&B) Downregulation of TRIM33 promoted colony formation in BGC-823 and SGC-7901 cells. (C&D) After 24 h, the number of cells passing through the Transwell membrane was higher in the si-TRIM33 group than in the control group (×100 magnification, corresponding to a scale of 200 μm). (E&F) After 12, 24, 48, 72, 96, 120, and 144 h, the width of the residual scratch was narrower in the si-TRIM33 group than in the control group (×100 magnification, corresponding to a scale of 200 μm). * P < .05, ** P < .01.

    Techniques Used: Membrane, Control

    Knockdown of TRIM33 upregulated TGF-β expression. (A) ELISA analysis of TGF-β expression in the si-TRIM33 and control groups identified that knockdown of TRIM33 upregulated TGF-β expression, suggesting activation of the TGF-β signaling pathway. (B&C) Western blot analysis of the expression of proteins in the TGF-β signaling pathway in control, si-NC, and si-TRIM33 cells. Expression of p-Smad2 (Ser465/467), Smad2, Smad3, Smad4, vimentin, and N-Cadherin was upregulated, and E-Cadherin expression was downregulated, in si-TRIM33 cells. * P < .05, ** P < .01.
    Figure Legend Snippet: Knockdown of TRIM33 upregulated TGF-β expression. (A) ELISA analysis of TGF-β expression in the si-TRIM33 and control groups identified that knockdown of TRIM33 upregulated TGF-β expression, suggesting activation of the TGF-β signaling pathway. (B&C) Western blot analysis of the expression of proteins in the TGF-β signaling pathway in control, si-NC, and si-TRIM33 cells. Expression of p-Smad2 (Ser465/467), Smad2, Smad3, Smad4, vimentin, and N-Cadherin was upregulated, and E-Cadherin expression was downregulated, in si-TRIM33 cells. * P < .05, ** P < .01.

    Techniques Used: Knockdown, Expressing, Enzyme-linked Immunosorbent Assay, Control, Activation Assay, Western Blot

    Knockdown of TRIM33 promoted GC growth in vivo. (A) The xenograft model of TRIM33-knockdown revealed that tumors were significantly larger in si-TRIM33 animals than in controls. (B&C) Immunohistochemical analysis identified that the protein levels of TRIM33, p-Smad2 (Ser465/467), Smad2, Smad3, Smad4, vimentin, and N-Cadherin were increased, and levels of E-Cadherin were decreased, in xenograft tumors from the si-TRIM33 group (×100 and ×400 magnification in left- and right-hand side images, corresponding to a scale of 200 and 50 μm, respectively).
    Figure Legend Snippet: Knockdown of TRIM33 promoted GC growth in vivo. (A) The xenograft model of TRIM33-knockdown revealed that tumors were significantly larger in si-TRIM33 animals than in controls. (B&C) Immunohistochemical analysis identified that the protein levels of TRIM33, p-Smad2 (Ser465/467), Smad2, Smad3, Smad4, vimentin, and N-Cadherin were increased, and levels of E-Cadherin were decreased, in xenograft tumors from the si-TRIM33 group (×100 and ×400 magnification in left- and right-hand side images, corresponding to a scale of 200 and 50 μm, respectively).

    Techniques Used: Knockdown, In Vivo, Immunohistochemical staining



    Similar Products

    rabbit antibody against human trim33  (Proteintech)
    93
    Proteintech rabbit antibody against human trim33
    The expression of <t>TRIM33</t> in pan-cancer, and association between TRIM33 expression and the survival of patients with GC. (A) TRIM33 expression in 31 tumors from TCGA database. Red bars represent tumor samples, blue bars represent normal tissue samples. (B) OS, FPS, and PPS curves in patients with GC. (C) Survival curves of different pTNM stages in patients with GC. (D) Survival curves of different pT stages in patients with GC. * P < .05, ** P < .01, *** P < .001 versus normal tissue samples.
    Rabbit Antibody Against Human Trim33, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+antibody+against+human+trim33/pmc09358585-32-1-12?v=Proteintech
    Average 93 stars, based on 1 article reviews
    rabbit antibody against human trim33 - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    The expression of TRIM33 in pan-cancer, and association between TRIM33 expression and the survival of patients with GC. (A) TRIM33 expression in 31 tumors from TCGA database. Red bars represent tumor samples, blue bars represent normal tissue samples. (B) OS, FPS, and PPS curves in patients with GC. (C) Survival curves of different pTNM stages in patients with GC. (D) Survival curves of different pT stages in patients with GC. * P < .05, ** P < .01, *** P < .001 versus normal tissue samples.

    Journal: Technology in Cancer Research & Treatment

    Article Title: Downregulation of TRIM33 Promotes Survival and Epithelial–Mesenchymal Transition in Gastric Cancer

    doi: 10.1177/15330338221114505

    Figure Lengend Snippet: The expression of TRIM33 in pan-cancer, and association between TRIM33 expression and the survival of patients with GC. (A) TRIM33 expression in 31 tumors from TCGA database. Red bars represent tumor samples, blue bars represent normal tissue samples. (B) OS, FPS, and PPS curves in patients with GC. (C) Survival curves of different pTNM stages in patients with GC. (D) Survival curves of different pT stages in patients with GC. * P < .05, ** P < .01, *** P < .001 versus normal tissue samples.

    Article Snippet: The rabbit antibody against human TRIM33 (Cat No. 55374-1-AP) was purchased from ProteinTech; rabbit antibodies against human phospho-Smad2 (p-Smad2; #18338), Smad2 (#5339), Smad3 (#9523), Smad4 (#46535), vimentin (#5741), N-Cadherin (#13116), E-Cadherin (#3195), and β-actin (#5125), as well as a horseradish peroxidase-linked goat anti-rabbit antibody (#7074), were purchased from Cell Signaling Technology.

    Techniques: Expressing

    Knockdown of TRIM33 promoted the proliferation of BGC-823 and SGC-7901 cells. (A&B) Western blot analysis of TRIM33 expression in GES, BGC-823, MGC-803, and SGC-7901 cell lines. (C&D) Western blot analysis of TRIM33 protein expression in cells transfected with si-TRIM33 encoding plasmids. (E) CCK8 assays were used to measure BGC-823 and SGC-7901 cell viability in the control and si-TRIM33-transfected group; the viability of the si-TRIM33 transfection groups was enhanced. (F&G) EdU assays were used to evaluate proliferation in the control and si-TRIM33 transfection groups in BGC-823 cells; the percentage of EdU-positive cells in the si-TRIM33 group was significantly greater than in the control group. * P < .05, ** P < .01; ns, non-significant.

    Journal: Technology in Cancer Research & Treatment

    Article Title: Downregulation of TRIM33 Promotes Survival and Epithelial–Mesenchymal Transition in Gastric Cancer

    doi: 10.1177/15330338221114505

    Figure Lengend Snippet: Knockdown of TRIM33 promoted the proliferation of BGC-823 and SGC-7901 cells. (A&B) Western blot analysis of TRIM33 expression in GES, BGC-823, MGC-803, and SGC-7901 cell lines. (C&D) Western blot analysis of TRIM33 protein expression in cells transfected with si-TRIM33 encoding plasmids. (E) CCK8 assays were used to measure BGC-823 and SGC-7901 cell viability in the control and si-TRIM33-transfected group; the viability of the si-TRIM33 transfection groups was enhanced. (F&G) EdU assays were used to evaluate proliferation in the control and si-TRIM33 transfection groups in BGC-823 cells; the percentage of EdU-positive cells in the si-TRIM33 group was significantly greater than in the control group. * P < .05, ** P < .01; ns, non-significant.

    Article Snippet: The rabbit antibody against human TRIM33 (Cat No. 55374-1-AP) was purchased from ProteinTech; rabbit antibodies against human phospho-Smad2 (p-Smad2; #18338), Smad2 (#5339), Smad3 (#9523), Smad4 (#46535), vimentin (#5741), N-Cadherin (#13116), E-Cadherin (#3195), and β-actin (#5125), as well as a horseradish peroxidase-linked goat anti-rabbit antibody (#7074), were purchased from Cell Signaling Technology.

    Techniques: Knockdown, Western Blot, Expressing, Transfection, Control

    Downregulation of TRIM33 enhanced colony formation and migratory ability. (A&B) Downregulation of TRIM33 promoted colony formation in BGC-823 and SGC-7901 cells. (C&D) After 24 h, the number of cells passing through the Transwell membrane was higher in the si-TRIM33 group than in the control group (×100 magnification, corresponding to a scale of 200 μm). (E&F) After 12, 24, 48, 72, 96, 120, and 144 h, the width of the residual scratch was narrower in the si-TRIM33 group than in the control group (×100 magnification, corresponding to a scale of 200 μm). * P < .05, ** P < .01.

    Journal: Technology in Cancer Research & Treatment

    Article Title: Downregulation of TRIM33 Promotes Survival and Epithelial–Mesenchymal Transition in Gastric Cancer

    doi: 10.1177/15330338221114505

    Figure Lengend Snippet: Downregulation of TRIM33 enhanced colony formation and migratory ability. (A&B) Downregulation of TRIM33 promoted colony formation in BGC-823 and SGC-7901 cells. (C&D) After 24 h, the number of cells passing through the Transwell membrane was higher in the si-TRIM33 group than in the control group (×100 magnification, corresponding to a scale of 200 μm). (E&F) After 12, 24, 48, 72, 96, 120, and 144 h, the width of the residual scratch was narrower in the si-TRIM33 group than in the control group (×100 magnification, corresponding to a scale of 200 μm). * P < .05, ** P < .01.

    Article Snippet: The rabbit antibody against human TRIM33 (Cat No. 55374-1-AP) was purchased from ProteinTech; rabbit antibodies against human phospho-Smad2 (p-Smad2; #18338), Smad2 (#5339), Smad3 (#9523), Smad4 (#46535), vimentin (#5741), N-Cadherin (#13116), E-Cadherin (#3195), and β-actin (#5125), as well as a horseradish peroxidase-linked goat anti-rabbit antibody (#7074), were purchased from Cell Signaling Technology.

    Techniques: Membrane, Control

    Knockdown of TRIM33 upregulated TGF-β expression. (A) ELISA analysis of TGF-β expression in the si-TRIM33 and control groups identified that knockdown of TRIM33 upregulated TGF-β expression, suggesting activation of the TGF-β signaling pathway. (B&C) Western blot analysis of the expression of proteins in the TGF-β signaling pathway in control, si-NC, and si-TRIM33 cells. Expression of p-Smad2 (Ser465/467), Smad2, Smad3, Smad4, vimentin, and N-Cadherin was upregulated, and E-Cadherin expression was downregulated, in si-TRIM33 cells. * P < .05, ** P < .01.

    Journal: Technology in Cancer Research & Treatment

    Article Title: Downregulation of TRIM33 Promotes Survival and Epithelial–Mesenchymal Transition in Gastric Cancer

    doi: 10.1177/15330338221114505

    Figure Lengend Snippet: Knockdown of TRIM33 upregulated TGF-β expression. (A) ELISA analysis of TGF-β expression in the si-TRIM33 and control groups identified that knockdown of TRIM33 upregulated TGF-β expression, suggesting activation of the TGF-β signaling pathway. (B&C) Western blot analysis of the expression of proteins in the TGF-β signaling pathway in control, si-NC, and si-TRIM33 cells. Expression of p-Smad2 (Ser465/467), Smad2, Smad3, Smad4, vimentin, and N-Cadherin was upregulated, and E-Cadherin expression was downregulated, in si-TRIM33 cells. * P < .05, ** P < .01.

    Article Snippet: The rabbit antibody against human TRIM33 (Cat No. 55374-1-AP) was purchased from ProteinTech; rabbit antibodies against human phospho-Smad2 (p-Smad2; #18338), Smad2 (#5339), Smad3 (#9523), Smad4 (#46535), vimentin (#5741), N-Cadherin (#13116), E-Cadherin (#3195), and β-actin (#5125), as well as a horseradish peroxidase-linked goat anti-rabbit antibody (#7074), were purchased from Cell Signaling Technology.

    Techniques: Knockdown, Expressing, Enzyme-linked Immunosorbent Assay, Control, Activation Assay, Western Blot

    Knockdown of TRIM33 promoted GC growth in vivo. (A) The xenograft model of TRIM33-knockdown revealed that tumors were significantly larger in si-TRIM33 animals than in controls. (B&C) Immunohistochemical analysis identified that the protein levels of TRIM33, p-Smad2 (Ser465/467), Smad2, Smad3, Smad4, vimentin, and N-Cadherin were increased, and levels of E-Cadherin were decreased, in xenograft tumors from the si-TRIM33 group (×100 and ×400 magnification in left- and right-hand side images, corresponding to a scale of 200 and 50 μm, respectively).

    Journal: Technology in Cancer Research & Treatment

    Article Title: Downregulation of TRIM33 Promotes Survival and Epithelial–Mesenchymal Transition in Gastric Cancer

    doi: 10.1177/15330338221114505

    Figure Lengend Snippet: Knockdown of TRIM33 promoted GC growth in vivo. (A) The xenograft model of TRIM33-knockdown revealed that tumors were significantly larger in si-TRIM33 animals than in controls. (B&C) Immunohistochemical analysis identified that the protein levels of TRIM33, p-Smad2 (Ser465/467), Smad2, Smad3, Smad4, vimentin, and N-Cadherin were increased, and levels of E-Cadherin were decreased, in xenograft tumors from the si-TRIM33 group (×100 and ×400 magnification in left- and right-hand side images, corresponding to a scale of 200 and 50 μm, respectively).

    Article Snippet: The rabbit antibody against human TRIM33 (Cat No. 55374-1-AP) was purchased from ProteinTech; rabbit antibodies against human phospho-Smad2 (p-Smad2; #18338), Smad2 (#5339), Smad3 (#9523), Smad4 (#46535), vimentin (#5741), N-Cadherin (#13116), E-Cadherin (#3195), and β-actin (#5125), as well as a horseradish peroxidase-linked goat anti-rabbit antibody (#7074), were purchased from Cell Signaling Technology.

    Techniques: Knockdown, In Vivo, Immunohistochemical staining